造血因子在急性白血病中的研究进展
Research Progress of Hematopoietic Factors in Acute Leukemia
DOI: 10.12677/ACM.2022.12111470, PDF,   
作者: 孙 琦, 周厚法：青海大学研究生院，青海 西宁；李文倩*：青海省人民医院血液科，青海 西宁
关键词: 急性白血病；造血因子；造血生长因子；骨髓微环境；Acute Leukemia； Hematopoietins； Hematopoietic Cell Growth Factor； Bone Marrow Microenvironment
摘要: 急性白血病(acute leukemia, AL)是造血干细胞恶性克隆性疾病，在我国AL发病率为2.78/10万人口，且呈逐年提高趋势，严重威胁公众健康，目前AL主要利用有创性的骨髓细胞学进行临床预后及治疗效果评估，造血因子作为骨髓微环境重要组成成分，通过自分泌或旁分泌促进急性白血病的发生、发展，甚至也参与其耐药的发生，因此阐明急性白血病中常见造血生长因子表达水平的变化及其在AL中的研究进展，有利于进一步探究急性白血病发生发展及其预后，并为临床治疗新方向提供思路，本文选取目前研究较多的造血因子(EPO, TPO, FLT3L, IFN-γ)作一综述，为进一步临床研究提供参考。
Abstract: Acute leukemia (acute leukemia, AL) is a malignant clonal disease of hematopoietic stem cells, the incidence of AL in China is 2.78/100,000 population, and it is increasing year by year, seriously threatening public health. At present, AL mainly uses invasive bone marrow cytology for clinical prognosis and treatment effect evaluation, hematopoietic factors as an important component of the bone marrow microenvironment, through autocrine or paracrine to promote the occurrence and development of acute leukemia, and even participate in the occurrence of its drug resistance. Therefore, elucidating the changes in the expression level of common hematopoietic growth factors in acute leukemia and its research progress in AL is conducive to further exploring the occurrence and development of acute leukemia and its prognosis, and provide new directions for clinical treatment. This paper selects the hematopoietic factors (EPO, TPO, FLT3L, IFN-γ) that have been studied more at present for a review, providing a reference for further clinical research.
文章引用：孙琦, 李文倩, 周厚法. 造血因子在急性白血病中的研究进展[J]. 临床医学进展, 2022, 12(11): 10199-10205. https://doi.org/10.12677/ACM.2022.12111470

参考文献

[1] Quesada, A.E., Hu, Z., Routbort, M.J., et al. (2018) Mixed Phenotype Acute Leukemia Contains Heterogeneous Genetic Mutations by Next-Generation Sequencing. Oncotarget, 9, 8441-8449. [Google Scholar] [CrossRef] [PubMed]
[2] 张佳丽, 姜华. 生命关怀护理对哈尔滨市某医院青少年白血病患者认知情绪调节及心理弹性的影响[J]. 医学与社会, 2018, 31(12): 67-68.
[3] 杨莹, 关红梅, 王舒, 等. 脑脊液与血清IGF-1、IGF-2、IGFBP-3、IL-2、IL-6、IL-8在急性淋巴细胞性白血病中的表达水平及意义[J]. 热带医学杂志, 2020, 20(11): 1438-1441.
[4] 宋辉, 于艺冰, 郭媛媛. FMS样酪氨酸激酶3配体在急性髓系白血病患者血清中的表达及其临床意义[J]. 东南大学学报(医学版), 2021, 40(1): 41-45.
[5] Galán-Díez, M., Cues-ta-Domínguez, Á. and Kousteni, S. (2018) The Bone Marrow Microenvironment in Health and Myeloid Malignancy. Cold Spring Harbor Perspectives in Medicine, 8, a031328. [Google Scholar] [CrossRef] [PubMed]
[6] Nekoui, A. and Blaise, G. (2017) Erythropoietin and Nonhema-topoietic Effects. The American Journal of the Medical Sciences, 353, 76-81. [Google Scholar] [CrossRef] [PubMed]
[7] 冯俊月, 马宝新, 李跃荣. 促红细胞生成素及受体在肿瘤中的研究进展[J]. 现代肿瘤医学, 2020, 28(18): 3264-3267.
[8] 苏娜, 柳金. 急性白血病患者血清促红细胞生成素浓度检测意义[J]. 南方医科大学学报, 2009, 29(11): 2321-2323.
[9] 张群秀, 王丽娜, 祝微, 等.补肾生血法对化疗后骨髓抑制小鼠造血生长因子GM-CSF, EPO, TPO mRNA表达的影响[J]. 时珍国医国药, 2019, 30(8): 1836-1839.
[10] 陈陆昕, 谷冬梅, 罗微. 血小板生成素的研究新进展[J]. 中华全科医学, 2021, 19(2): 290-292.
[11] 张勇, 孔佩艳, 曾东风, 等. 骨髓TPO及受体c-MPL表达变化在急性髓系白血病化疗中的意义[J]. 肿瘤防治研究, 2012, 39(5): 511-514.
[12] Li, H., Zhao, N., Li, Y., et al. (2018) c-MPL Is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem Cells. Stem Cells (Dayton, Ohio), 36, 1685-1696. [Google Scholar] [CrossRef] [PubMed]
[13] Audiger, C. and Lesage, S. (2020) FLT3 Ligand Is Dispensable for the Final Stage of Type 1 Conventional Dendritic Cell Differentiation. Journal of Immunology (Baltimore, Md.: 1950), 205, 2117-2127. [Google Scholar] [CrossRef] [PubMed]
[14] Tort Tarrés, M., Aschenbrenner, F., Maus, R., et al. (2019) The FMS-Like Tyrosine Kinase-3 Ligand/Lung Dendritic Cell Axis Contributes to Regulation of Pulmonary Fibrosis. Thorax, 74, 947-957. [Google Scholar] [CrossRef] [PubMed]
[15] Daver, N., Schlenk, R.F., Russell, N.H., et al. (2019) Target-ing FLT3 Mutations in AML: Review of Current Knowledge and Evidence. Leukemia, 33, 299-312. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, X., Sexauer, A. and Levis, M. (2014) Bone Marrow Stro-ma-Mediated Resistance to FLT3 Inhibitors in FLT3-ITD AML IS Mediated by Persistent Activation of Extracellular Regulated Kinase. British Journal of Haematology, 1, 61-72. [Google Scholar] [CrossRef] [PubMed]
[17] Peterlin, P., Gaschet, J., Guillaume, T., et al. (2021) A New Cytokine-Based Dynamic Stratification during Induction Is Highly Pre-dictive of Survivals in Acute Myeloid Leukemia. Cancer Medicine, 10, 642-648. [Google Scholar] [CrossRef] [PubMed]
[18] Tsapogas, P., Mooney, C.J., Brown, G., et al. (2017) The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis. International Journal of Molecular Sciences, 18, Article No. 1115. [Google Scholar] [CrossRef] [PubMed]
[19] Binder, S., Luciano, M. and Horejs-Hoeck, J. (2018) The Cytokine Network in Acute Myeloid Leukemia (AML): A Focus on Pro- and Anti-Inflammatory Mediators. Cytokine & Growth Factor Reviews, 43, 8-15. [Google Scholar] [CrossRef] [PubMed]
[20] 刘亚强, 仝义娜, 仝宜芳. 急性白血病患儿血清铁调素与白细胞介素-6表达水平的临床意义[J]. 黑龙江医学, 2020, 44(3): 371-372.
[21] Zhang, T.Y., Dutta, R., Benard, B., et al. (2020) IL-6 Blockade Reverses Bone Marrow Failure Induced by Human Acute Myeloid Leukemia. Science Transla-tional Medicine, 12, eaax5104. [Google Scholar] [CrossRef] [PubMed]
[22] 任峰, 姜俊秋. 不同类型急性白血病患者血清IFN-γ、TGF-β、IL-6和IL-17水平变化及其预后判定分析[J]. 中国实验诊断学, 2020, 24(5): 796-799.
[23] 仲华, 林志强, 薄德映, 等. TGF-β1、GM-CSF及TNF-α对急性髓系白血病患者病情转归的评估[J]. 分子诊断与治疗杂志, 2021, 13(5): 807-810+815.
[24] 杨娜, 朱澜, 邢立娟, 等. 急性白血病患者血清SDF-1、GM-CSF、α-HBDH的表达水平及临床意义[J]. 中国实验诊断学, 2018, 22(8): 1416-1418.
[25] Lei, M., Liu, L. and Wu, D. (2019) Priming with GM-CSF Instead of G-CSF Enhances CAG-Induced Apoptosis of Acute Monocytic Leukemia Cells in Vitro. Cancer Chemotherapy and Pharmacology, 84, 265-273. [Google Scholar] [CrossRef] [PubMed]
[26] Allahbakhshian Farsani, M., Kamel, M., Mehrpouri, M., et al. (2020) The Expression of Interferon Gamma (IFN-γ) and Interleukin 6 (IL6) in Patients with Acute Lymphoblastic Leu-kemia (ALL). Pathology Oncology Research: POR, 26, 461-466. [Google Scholar] [CrossRef] [PubMed]
[27] 周歌, 王叨, 刘玉峰. PD1/PD-L1通路在急性白血病中作用的研究进展[J]. 中国小儿血液与肿瘤杂志, 2020, 25(1): 50-52.
[28] Assi, R., Kantarjian, H., Ravandi, F., et al. (2018) Immune Therapies in Acute Myeloid Leukemia: A Focus on Monoclonal Antibodies and Immune Checkpoint Inhibitors. Current Opinion in Hematology, 25, 136-145. [Google Scholar] [CrossRef] 
[29] 程诚. PD-1/PD-L1在急性髓系白血病中的表达及其对PD-1~+NK细胞抗肿瘤作用的影响[D]: [硕士学位论文]. 郑州: 郑州大学, 2021.

为你推荐